DHCPL, HSA Announcements

HSA DHCPL: Plaquenil® (Hydroxychloroquine sulfate) – Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms

Sep 29
By DocMed

Plaquenil® (Hydroxychloroquine sulfate) – Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms

You must be healthcare professional to view this content.

EXPLORE

Daily Practice: In The Office with Dr Kok Wai Leong, Senior Consultant Dermatologist

Seizures Provoked by Over-the-counter Cough and Cold Medications in an Elderly Patient

Promoting Hair Regrowth and Scalp Health: Synergistic Benefits of CG210® Forte and Viviscal™ PRO in the Management of Thinning Hair and Alopecia

Battling Dengue: A Disease No Longer Limited To Tropical Regions

Pounds of Trouble: How Obesity May Spark Inflammation and Genetic Mutations in Breast Cancer Cells

HSA DHCPL: Plaquenil® (Hydroxychloroquine sulfate) – Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms

You must be healthcare professional to view this content.

EXPLORE

RELATED CONDITIONS &

PROCEDURES

About Us

Our Section

Connect with Us

My Account